Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

RX-21101 selected for NCL preclinical program
08-15-2015
SHARING OPTIONS:

ROCKVILLE, Md.—The National Cancer Institute’s Nanotechnology Characterization Laboratory (NCL) has selected Rexahn Pharmaceuticals Inc.’s RX-21101, a polymer conjugated form of docetaxel containing a signaling moiety that directs it into tumors, for its preclinical characterization program to help advance the drug candidate toward human clinical trials. The NCL will conduct several preclinical studies of RX-21101—including physiochemical characterization, in-vitro cytotoxicity/hematology/immunology and in-vivo rodent pharmacokinetic studies—that will, along with other work by Rexahn, be the basis of filing an IND application to begin Phase 1 clinical testing. The NCL was established to aid in translating promising nanotechnology-based therapeutics for the treatment of cancer, together with the National Institute of Standards and Technology and the U.S. Food and Drug Administration.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.